Bone marrow cell injector shows promise for CAD (coronary artery disease)
This article was originally published in Clinica
Executive Summary
The first randomised, controlled trial to evaluate the clinical effects of directly injecting bone marrow cells into blood- and oxygen-starved heart muscle using a catheter-based technique rather than open-chest surgery has shown significant improvements in both exercise capacity and the heart's ability to effectively pump blood.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.